TerminatedNCT00159757

12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients

Medication studyAges 18+HungarySchizophrenia

The study in practice

Understand this study

Listed age limits: from 18 years.

Listed locations: Budapest and 7 more locationsSee all locations and recruitment
Study phase: Phase 4

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateNovember 2003

Recruitment status: Terminated
Enrollment listed in the registry: 150
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 4
Locations: Hungary
Age range: Over 18 Years
Official registry ID: NCT00159757
Official title: Show the full official title
12 Week Open Label, Multicenter, Non-Comparative Switch Study Evaluating Efficacy, Tolerability And Safety Of Oral Ziprasidone In Treatment Of Patients Suffering From Schizophrenia Who Have Already Been Treated With An Other Antipsychotic.

Terminated

Budapest · Debrecen · Esztergom

5 more locations

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Does this study involve medication?

Yes. The study involves medication, including ziprazidone.

Who can participate?

Listed age limits: from 18 years.

Is this study still recruiting?

The registry lists this study as terminated.